SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia

详细信息	查看全文 | 推荐本文 |

• 作者：Francesca Romana Mauro^a ; Giuseppe Bandini^b ; Giovanni Barosi^c ; ^{barosig@smatteo.pv.it} ; Atto Billio^d ; Maura Brugiatelli^e ; Antonio Cuneo^f ; Francesco Lauria^g ; Vincenzo Liso^h ; Monia Marchettiⁱ ; Giovanna Meloni^a ; Marco Montillo^j ; Pierluigi Zinzani^b ; Sante Tura^k
• 关键词：Chronic lymphocytic leukemia ; Guideline ; Recommendation ; Rituximab ; Alemtuzumab
• 刊名：Leukemia Research
• 出版年：2012
• 期刊代码：186_01452126
• 类别：med
• 出版时间：April, 2012
• 卷：36
• 期：4
• 页码：459-466
• 文件大小：273 K

摘要

By using GRADE system we updated the guidelines for management of CLL issued in 2006 from SIE, SIES and GITMO group. We recommended fludarabine, cyclophosphamide, rituximab (FCR) in younger and selected older patients with a good fitness status, no unfavourable genetics (deletion 17p and/or p53 mutations), and a less toxic treatment in nonfit and elderly patients. In patients without unfavourable genetics, relapsed after 24 months the same initial treatment including rituximab can be considered. In patients with unfavourable genetics, refractory or relapsed within 24 months from a prior fludarabine-based treatment, allogeneic SCT or experimental treatments should be given.